8-K

UNITEDSTATESSECURITIES AND EXCHANGE COMMISSIONWashington, DC 20549

FORM8-K

CURRENTREPORT

Pursuantto Section 13 or 15(d) of theSecurities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 29, 2020

ENOCHIANBIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

+1(786)888-1685

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company      ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

| 1 |

| --- |

Item8.01 Other Events.

On April 29, 2020, Enochian Biosciences, Inc. distributed a Letter to its Shareholders from its Chairman of the Board and Executive Vice-Chair. A copy of the letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Item 8.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The Company undertakes no duty or obligation to update or revise information included in this Report or the Exhibit.

Item9.01 Financial Statements and Exhibits

| 2 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| 3 |

| --- |

Exhibit 99.1

Dear Shareholders,

Thank you for your patience.

Since our initial funding in 2018, Enochian Biosciences has gone from a "one product strategy" to a Company with a “multi-product strategy" based on platforms in both cancer and viruses. You can see more about this on the website www.enochianbio.com

As is the case with all strong Biotech companies, we issue public statements only when we have something worth saying (e.g., scientific presentations.) In that regard, we issued:

- In June 2019 a press release announcing that Enochian’s inventor was named to two important scientific committees of the American Society of Cell and Gene Therapy (ASCGT);

- In November 2019, a press release announcing an agreement in principle to acquire an exclusive license for a novel hepatitis B virus cure or treatment;

- In December 2019 a press release and link to the scientific presentation at HEP DART of that novel potential cure or treatment for hepatitis B infection. The presentation was recognized as one of the best new therapies/novel strategies at the conference. Jon Cohen of Science magazine tweeted, “Intriguing novel mechanism for attacking Hepatitis B virus.” https://twitter.com/sciencecohen/status/1204891529275269120;

-In January 2020, a press release announcing the appointment of two new Board members; Gregg Alton, who held many senior positions at Gilead including as interim CEO, and Dr. Carol Brosgart, Clinical Professor of Medicine at the University of California, San Francisco (USCF), former senior advisor on hepatitis for the Centers for Disease Control and Prevention (CDC) and Pharmaceutical and Biotech Executive and Board Member;

-In February 2020, a press release announcing the acquisition of the exclusive license for the hepatitis B virus potential cure or treatment, and;

-In February 2020, a press release announcing an FDA interact meeting being scheduled for ENOB-HV-01, a potential cure for HIV.

| 1 |

| --- |

Recently, we announced that three abstracts would be presented at the ASCGT annual conference in May (www.asgct.org). Two of the abstracts relate to ENOB-HV-01, our approach to potentially less toxic and more effective non-myeloablative transplantation to cure HIV. The third abstract provides additional data regarding the effectiveness of our newest pipeline, the potential cure, or effective treatment of hepatitis B infections. The meeting will now be held virtually. As soon as the presentations are live, we will issue a press release explaining the findings and post the presentations and slides for non-scientific audiences. We will also issue an 8-k for the use of potential investors who do not follow press releases or scientific conferences.

Overall, these public announcements reflect our public statement that thus far, the scientific findings of Enochian have exceeded our expectations.

Based on our substantial progress, Enochian will pursue major institutions and investors in the coming months.

We look forward to being able to provide additional updates over time. We remain very excited about the Enochian pipeline and our scientific advances.

We remain yours sincerely,

Enochian Biosciences

Rene Sindlev & Dr. Mark Dybul

| 2 |

| --- |